Abstract
BackgroundTofacitinib is an oral JAK inhibitor for the treatment of RA.ObjectivesTo evaluate tofacitinib 5 and 10 mg twice daily (BID) efficacy in patients (pts) with moderate vs severe RA.MethodsTofacitinib 5...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
